Gossamer Bio, Inc. announced that it has received $100 million in funding from Arch Venture Partners, L.P., Omega Fund Management UK LLP, and other investors
January 04, 2018
Share
Gossamer Bio, Inc. announced that it has raised $100,000,000 in its seed round of funding co-led by Arch Venture Partners, L.P. and Omega Fund Management UK LLP on January 4, 2018. The company issued series A preferred stock in the transaction. As part of the transaction, Richard Lim and Otello Stampacchia of Omega Fund Management UK LLP and Kristina Burow and Robert Nelsen of Arch Venture Partners, L.P. The company will issue securities pursuant to exemption provided under Regulation D.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gossamer Bio, Inc. announced that it has received $100 million in funding from Arch Venture Partners, L.P., Omega Fund Management UK LLP, and other investors
GOSSAMER BIO, INC. 
